PROTACing against liver cancer

IF 72.5 1区医学 Q1 ONCOLOGY

Nature Reviews Cancer Pub Date : 2025-03-05 DOI:10.1038/s41568-025-00805-y

Anna Dart

引用次数: 0

Abstract

Yang et al. developed a proteolysis-targeting chimera (PROTAC) 753b, which targets BCL-xL and BCL-2 to the E3 ubiquitin ligase VHL, and showed that it removed senescent cells specifically from the liver, reducing the progression of chronic metabolic liver disease to liver cancer.

查看原文本刊更多论文

Yang等人开发了一种蛋白水解靶向嵌合体（PROTAC）753b，它能将BCL-xL和BCL-2靶向E3泛素连接酶VHL，结果表明它能特异性地清除肝脏中的衰老细胞，减少慢性代谢性肝病向肝癌的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.